July 16, 2021 | Source: Thelansis Knowledge Partners LLP.

According to Thelansis the global Chemotherapy Induced Peripheral Neuropathy (CIPN) in 8 MM countries estimated to be USD ~2.6 BN in 2020, USD and USD 4.7 BN by the end of 2030 (10 years of markets forecasting). They attribute the high growth to the launches of Opioid analgesics, Alpha-2-delta antagonist, SNRI, Tricyclic antidepressants, Analgesic and Others,.

Epidemiology and patient segmentation:

According to Thelansis the estimated total patient pool of chemotherapy induced peripheral neuropathy (CIPN) in 8 MM countries are reported to be 3.35 MN in 2020, 3.47 MN in 2025 and 3.57 MN by 2030. Overall growth of the patient pool for CIPN in 8MM countries is majorly due to patient available to each treatment modalities and newly diagnosed patient pool.

Disease overview, Epidemiology (Incidence, prevalence, grade-wise and stage-wise), patient segmentation is reported based on the following segmentation- surgery + chemotherapy, surgery + chemotherapy + radiotherapy, chemotherapy + radiotherapy, chemotherapy only. Severity specific incidence of CIPN categorized based on mild, moderate and severe conditions in the report.


Competitive Landscape:

Currently, there is no approved therapy for the treatment of CIPN. The market is mainly dominated by off-label therapies such as steroids, antidepressants, antiepileptics, opioids and procedural therapies (Electrical nerve stimulation, Occupational therapy, Physical therapy, and Acupuncture).

Emerging therapies: As per Thelansis, key player are into developing therapies for the treatment of CIPN are:

SP-04 (PledOx) /Solasia,
Halneuron, / Wex Pharmaceutical and
E-52862 / Esteve Pharmaceuticals,
ART-123 (thrombomodulin alfa) /Asahi Kasei Pharma,
APX3330 / Apexian Pharmaceuticals.

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)
- Data Inputs with sourcing
- Market Event and Product Event
- Country specific Forecast Model
- Market uptake and patient share uptake
- Attribute Analysis
- Analog Analysis
- Disease burden and pricing scenario
- Summary and Insights

Landscape Developmental Overview

There is currently only one asset in the Phase III (PledOx), and three in Phase II. However, out of the Phase II assets, two competitors have not registered any major recent event
Most of the therapies are concentrated in preclinical stages at the moment which translates into both, clinical unmet need and market opportunity
Overarching, there are two key assets currently in development for CIPN with approval potential
Initial positive results have also generated positive sentiment around the assets. There is virtually no resonating share of voice for other assets considering the immediate future

Key Opinion Leaders (KOL) Insights for
SP-04 (PledOx),
Halneuron, E-52862,
ART-123 (thrombomodulin alfa),
APX3330

KOL Opinion on following parameters,
Comments on Drug’s Potential,
Prognostic factors
Clinical endpoint
Disease burden
Referral pattern
Efficacy and side effects
Unmet needs,
Disease presentation,
Diagnosis
Symptomatic treatment CIPN ,
Non pharmacological intervention,
Reimbursement of CIPN therapy

Clinical Trial Assessment-
Detailed clinical trial data analysis and key product positioning includes trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps in determining the potential of the key assets as well as their probable filing and launch date.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Report TOC

1. CIPN – Key Findings Summary
1.1. Commercial findings
2 CIPN Introduction
2.1 Chemotherapy-Induced Peripheral Neuropathy (CIPN)
2.2 Symptoms of CIPN
2.3 Grading of chemotherapy-induced peripheral neuropathy
2.4 Pathophysiology of CIPN
2.5 Chemotherapy-Induced Peripheral Neuropathy: Clinical Presentation
2.6 Genetics of Chemotherapy-Induced Peripheral Neuropathy
2.7 Diagnosis of CIPN
3. Epidemiology Research
3.1 Epidemiology Outlook
3.2 8MM Epidemiology Outlook
3.3 Country specific Epidemiology scenario
3.3.1 USA Epidemiology Scenario
3.3.2 EU5 Epidemiology Scenario
3.3.3 Germany Epidemiology Scenario
3.3.4 France Epidemiology Scenario
3.3.5 Italy Epidemiology Scenario
3.3.6 Spain Epidemiology Scenario
3.3.7 UK Epidemiology Scenario
3.3.8 Japan Epidemiology Scenario
3.3.9 China Epidemiology Scenario
4. Market Outlook
4.1 Market Outlook
4.2 8MM CIPN Market
4.3 8MM CIPN Market Forecast – Till 2030
4.4 Market Forecast USA – Till 2030
4.5 Market Forecast Germany – Till 2030
4.6 Market Forecast France – Till 2030
4.7 Market Forecast Italy – Till 2030
4.8 Market Forecast Spain – Till 2030
4.9 Market Forecast UK – Till 2030
4.10 Market Forecast Japan– Till 2030
4.11 Market Forecast China – Till 2030
5. Competitive Landscape
5.1 Marketed Therapies
5.2 Preventive Drugs for CIPN
5.3 Symptomatic Treatment of CIPN
5.4 Unmet Needs
5.5 Pipeline Therapies
5.5.1 Phase III Therapies
5.5.1.1 PledOx (Calmangafodipir)
5.5.1.2 Halneuron (tetrodotoxin)
5.5.1.3 APX3330
5.5.1.4 ART-123 (thrombomodulin alfa)
5.5.1.5 E-52862
5.5.1.6 MN-166 (ibudilast)
5.6 Pre-clinical/Research assets
5.7 Inactive Therapies
5.7.1 AL-309 (Endo International plc)
5.8 Key Opinion Leaders (KOL) Insights
5.8.1 Commentary for PledOx:
5.8.2 Commentary for Halneuron:
5.8.3 Commentary for E-52862:
6. Regulatory Framework Scenario
7. Clinical Trial Assessment – Current and Future Paradigm
7.1. Distribution of Primary Endpoints across trials
7.2. Distribution of Secondary Endpoints across trials
7.3. Key Investigator initiated trials
7.4. Attrition Analysis
8 Key Takeaways – CIPN Market
8.1 Epidemiology Patterns
8.2 Market Forecast
9. Report Methodology
10. About Thelansis

For more market outlook reports, please visit https://thelansis.com/.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published report across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial result throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Delivery office

Bengaluru- Embassy TechVillage, Kadabeesanahalli, Bengaluru-560013 India
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731

Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,

Email
[email protected],
[email protected]